<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yao Q</submitter><funding>NHLBI NIH HHS</funding><pagination>1410862</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11458440</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Human Aortic valve interstitial cells (AVICs) from calcific aortic valve disease (CAVD)-affected valves exhibit elevated fibrocalcific activity although the underlying mechanism remains incompletely understood. This study aimed to identify endogenous factors that promote aortic valve fibrocalcification.&lt;h4>Methods and results&lt;/h4>Proteomic analysis found increased cathepsin D levels in AVICs from CAVD-affected valves compared to AVICs from normal valves, and this finding was validated by immunoblotting. ELISA assay identified exacerbated release of cathepsin D by AVICs of diseased valves. Recombinant human cathepsin D upregulated the expression of runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), collagen I and collagen IV in human AVICs, resulting</pubmed_abstract><journal>Frontiers in cardiovascular medicine</journal><pubmed_title>Cathepsin D elevates the fibrocalcific activity in human aortic valve cells through the ERK1/2-Sox9 pathway.</pubmed_title><pmcid>PMC11458440</pmcid><funding_grant_id>R01 HL121776</funding_grant_id><pubmed_authors>Zhai Y</pubmed_authors><pubmed_authors>Ao L</pubmed_authors><pubmed_authors>The E</pubmed_authors><pubmed_authors>Fullerton DA</pubmed_authors><pubmed_authors>Yao Q</pubmed_authors><pubmed_authors>Nedumaran B</pubmed_authors><pubmed_authors>Meng X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cathepsin D elevates the fibrocalcific activity in human aortic valve cells through the ERK1/2-Sox9 pathway.</name><description>&lt;h4>Background&lt;/h4>Human Aortic valve interstitial cells (AVICs) from calcific aortic valve disease (CAVD)-affected valves exhibit elevated fibrocalcific activity although the underlying mechanism remains incompletely understood. This study aimed to identify endogenous factors that promote aortic valve fibrocalcification.&lt;h4>Methods and results&lt;/h4>Proteomic analysis found increased cathepsin D levels in AVICs from CAVD-affected valves compared to AVICs from normal valves, and this finding was validated by immunoblotting. ELISA assay identified exacerbated release of cathepsin D by AVICs of diseased valves. Recombinant human cathepsin D upregulated the expression of runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), collagen I and collagen IV in human AVICs, resulting</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-07-14T19:44:00.14Z</modification><creation>2025-04-03T23:48:47.531Z</creation></dates><accession>S-EPMC11458440</accession><cross_references><pubmed>39380629</pubmed><doi>10.3389/fcvm.2024.1410862</doi></cross_references></HashMap>